A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
30actual
Sites
21
Countries
Argentina, India, Taiwan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-28 | actual | When the study began enrolling |
| Primary completion | 2022-12-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-28 | actual | When this record first appeared on the registry |
| Results posted | 2024-09-24 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Osimertinib + Savolitinib
- Drug: Savolitinib + Placebo
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-05-09 · 23.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-08-16 · 10.7 MB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed